NEW YORK, January 10, 2017 /PRNewswire/ --
http://www.Financialbuzz.com - Small-cap companies are often overlooked, as they are considered to be high risk and volatile. To be a successful small-cap company investors need to look for consistent public filings and disclosures, potential innovative products, and understand the mechanics of different sectors. Keeping a strong operation, management, recent trending company news and a progressive future for the company is required. Popular small-cap companies belong in many different sectors - from solar companies, cannabis, biotechs, technology startups, agriculture and more. Cell MedX Corp. (OTC: CMXC), Pharmacyte Biotech Inc. (OTCQB: PMCB), Elite Pharmaceuticals Inc. (OTCQB: ELTP), Surna Inc. (OTCQB: SRNA), Greengro Technologies Inc. (OTC: GRNH)
Investors with high risk tolerance sometimes turn to volatile equities, as these low priced companies provide the high reward opportunities for these gamblers. Some low priced companies are traded on the senior exchanges, yet the major stock exchanges have very specific listing requirements. Most low priced companies that trade for less than $1 per share are primarily traded on the over-the-counter (OTC).
Cell MedX Corp. (OTCQB: CMXC) is a development stage focused on the development and commercialization of therapeutic products for patients with various diseases, including diabetes, Parkinson's disease, high blood pressure, and other health conditions. The Company, through its subsidiary Avyonce Cosmedics Inc., is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related diseases. The Company is currently developing a family of devices based on the eBalance Technology.
Yesterday, Cell MedX Corp. announced that it has "received its first eBalance Pro wellness devices ready for commercial distribution. These wellness devices are designed to promote general wellness and alleviate pain caused by chronic conditions such as: sciatica, neuropathy and arthritic pain. The eBalance Pro wellness device is an all-in-one, portable and fully automated microcurrent delivery system. This cutting-edge device's software uses biofeedback algorithms to identify specific and personalized microcurrent frequencies to alleviate what are, in many cases, painful conditions. This device is based on the Company's original eBalance Pro which continues to receive positive feedback. These observations are currently being conducted in Asia, Europe and North America."
CEO of Cell MedX Corp. Frank McEnulty, said in a statement, "We are very excited to receive the new model eBalance Pro wellness devices. Our excitement is based on our belief that our eBalance technology has effected positive change in the overall wellbeing of those currently engaged in observations."
Clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Pharmacyte Biotech Inc. (OTCQB: PMCB), cannabinoid therapy may offer potential for childhood brain cancers. The biotech's Chief Executive Officer, Kenneth L. Waggoner, commented, "It is clear that PharmaCyte is on the right track to developing targeted therapies for deadly cancers. The research reported in the journal Child's Nervous System, as well as other research, continues to demonstrate the anti-cancer properties of cannabinoids. We remain confident that Cell-in-a-Box® offers a safe and versatile platform for targeted chemotherapy delivery to cancerous tumors in the brain."
Elite Pharmaceuticals Inc. (OTCQB: ELTP) has met with the U.S. Food and Drug Administration for an end-of-review meeting to discuss steps that Elite can take to acquire approval of the company's abuse-deterrent opioid candidate for the management of moderate to severe acute pain drug, SequestOx™. "We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately." Elite Pharmaceuticals is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products.
Surna Inc. (OTCQB: SRNA) engineers and manufactures innovative technology and products that address the energy and resource intensive nature of indoor cultivation. Surna's current focus lies in supplying industrial solutions to commercial indoor cannabis cultivation facilities. The Company's products include Surna Chillers, Surna Reflectors, Hybrid Building and Air Sanitation. Its customers include state-regulated cannabis cultivation facilities, as well as traditional indoor agricultural facilities, including organic herb and vegetable producers.
Greengro Technologies Inc. (OTC: GRNH) provides green technologies focusing on indoor and outdoor agricultural science systems serving both the consumer and commercial farming markets. The company segments include GRNH, Vertical Hydrogarden Inc. and BP Gardens. GRNH provides design and consulting services to all agricultural divisions, including legalized Cannabis operations. It provides knowledge on designs and systems to maximize production for every crop cycle. VHI is a supplier of green agriculture products, including hydroponics, advanced nutrients, and vertical cultivation technology systems design and sales. BP Gardens uses methods to protect crops from detrimental environmental elements while generating market ready leafy green produce year-round in any climate.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbu zz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and PR marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com expects to be compensated six thousand dollars for financial news dissemination and PR services by a third party non affiliate for cell medx corp. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news PR media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: [email protected] , +1-877-601-1879
SOURCE FinancialBuzz.com
Share this article